Antibody WN1 222-5 mimics Toll-like receptor 4 binding in the recognition of LPS

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 51, 2012, Pages 20877-20882

  Gomery, Kathryn ^a   Mul̈ler Loennies, Sven ^b   Brooks, Cory L ^c   Brade, Lore ^b   Kosma, Paul ^d   Di Padova, Franco ^e   Brade, Helmut ^b   Evans, Stephen V ^a  

^a UNIVERSITY OF VICTORIA   (Canada)

^b RESEARCH CENTER BORSTEL   (Germany)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; WN 12225;

ARTICLE; CELL ACTIVATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ESCHERICHIA COLI; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; CARBOHYDRATES; ENDOTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HYDROGEN BONDING; LIGANDS; LIPIDS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MODELS, CHEMICAL; MODELS, MOLECULAR; PROTEIN BINDING; SHOCK, SEPTIC; TOLL-LIKE RECEPTOR 4;

ESCHERICHIA COLI;

EID: 84871393411     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1209253109     Document Type: Article

References (47)

1. Li J, Carr B, Goyal M, Gaieski DF (2011) Sepsis: The inflammatory foundation of pathophysiology and therapy. Hosp Pract (Minneap) 39(3):99-112.
2. Munford RS (2006) Severe sepsis and septic shock: The role of Gram-negative bacteremia. Annu Rev Pathol 1:467-496.
3. Park BS, et al. (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458(7242):1191-1195.
4. Kim HM, et al. (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130(5):906-917.
5. Stenutz R, Weintraub A, Widmalm G (2006) The structures of Escherichia coli Opolysaccharide antigens. FEMS Microbiol Rev 30(3):382-403.
6. Holst O, Müller-Loennies S (2007) Microbial polysaccharide structures. Comprehensive Glycoscience, ed Kamerling JP (Elsevier, Oxford), pp 123-179.
7. Tidswell M, et al.; Eritoran Sepsis Study Group (2010) Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 38(1):72-83.
8. Poltorak A, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282(5396):2085-2088.
9. Wittebole X, Castanares-Zapatero D, Laterre PF (2010) Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators In flamm 2010:568396.
10. Leon CG, Tory R, Jia J, Sivak O, Wasan KM (2008) Discovery and development of tolllike receptor 4 (TLR4) antagonists: A new paradigm for treating sepsis and other diseases. Pharm Res 25(8):1751-1761.
11. Ianaro A, Tersigni M, D'Acquisto F (2009) New insight in LPS antagonist. Mini Rev Med Chem 9(3):306-317.
12. Tidswell M, LaRosa SP (2011) Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis. Expert Rev Anti Infect Ther 9(5):507-520.
13. TateWJ, 3rd, Douglas H, Braude AI, WellsWW(1966) Protection against lethality of E. coli endotoxin with "O" antiserum. Ann N Y Acad Sci 133(2):746-762.
14. Chedid L, Parant M, Parant F, Boyer F (1968) A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol 100(2):292-306.
15. Di Padova FE, et al. (1993) A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun 61(9):3863-3872.
16. Pollack M, et al. (1997) Dual effects of LPS antibodies on cellular uptake of LPS and LPS-induced proinflammatory functions. J Immunol 159(7):3519-3530.
17. Di Padova F, et al. (1993) New anticore LPS monoclonal antibodies with clinical potential. Bacterial Endotoxin: Recognition and Effector Mechanisms, eds Levin J, Alving RS, Munford RS, Stutz PL (Elsevier, Amsterdam), Vol 2, pp 325 -335.
18. Cygler M, Wu S, Zdanov A, Bundle DR, Rose DR (1993) Recognition of a carbohydrate antigenic determinant of Salmonella by an antibody. Biochem Soc Trans 21(2):437-441.
19. Calarese DA, et al. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300(5628):2065-2071.
20. Villeneuve S, et al. (2000) Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: Molecular basis for serotype specificity. Proc Natl Acad Sci USA 97(15):8433-8438.
21. Jeffrey PD, et al. (1995) The x-ray structure of an anti-tumour antibody in complex with antigen. Nat Struct Biol 2(6):466-471.
22. Dyekjaer JD, Woods RJ (2006) Predicting the three-dimensional structures of anti-carbohydrate antibodies: combining comparative modeling and MD simulations. NMR Spectroscopy and Computer Modeling of Carbohydrates, eds Vliegenthar JFG, Woods RJ (American Chemical Society, Washington, DC), Vol 930, pp 203-219.
23. Menendez A, et al. (2008) A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J 22(5):1380-1392.
24. Calarese DA, et al. (2005) Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci USA 102(38):13372-13377.
25. Cygler M, Rose DR, Bundle DR (1991) Recognition of a cell-surface oligosaccharide of pathogenic Salmonella by an antibody Fab fragment. Science 253(5018):442-445.
26. Vulliez-Le Normand B, et al. (2008) Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody. Proc Natl Acad Sci USA 105(29):9976-9981.
27. Müller-Loennies S, Brade L, MacKenzie CR, Di Padova FE, Brade H (2003) Identification of a cross-reactive epitope widely present in lipopolysaccharide from enterobacteria and recognized by the cross-protective monoclonal antibody WN1 222-5. J Biol Chem 278(28):25618-25627.
28. Di Padova F, et al. (1996) Monoclonal antibodies to endotoxin core as a new approach in endotoxemia therapy Novel Therapeutic Strategies in the Treatment of Sepsis, eds Morrison DC, Ryan JL (Dekker, New York), pp 13-31.
29. Lefranc MP, et al. (2009) IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 37(database issue):D1006-D1012.
30. Gourdine JP, et al. (2008) High affinity interaction between a bivalve C-type lectin and a biantennary complex-type N-glycan revealed by crystallography and microcalorimetry. J Biol Chem 283(44):30112-30120.
31. Manavalan B, Basith S, Choi S (2011) Similar structures but different roles - An updated perspective on TLR structures. Front Physiol 2:41.
32. Raetz CR, Whitfield C (2002) Lipopolysaccharide endotoxins. Annu Rev Biochem 71: 635-700.
33. Aree T, Jacob J, Saenger W, Hoier H (1998) Crystal structure of α-cyclodextrin-aceto-nitrile- hexahydrate. Carbohydr Res 307(3-4):191-197.
34. Kastowsky M, Gutberlet T, Bradaczek H (1992) Molecular modelling of the three-dimensional structure and conformational flexibility of bacterial lipopolysaccharide. J Bacteriol 174(14):4798-4806.
35. Brooks CL, et al. (2010) Antibodies raised against chlamydial lipopolysaccharide antigens reveal convergence in germline gene usage and differential epitope recognition. Biochemistry 49(3):570-581.
36. Schroeder HW, Jr., Cavacini L (2010) Structure and function of immunoglobulins. J Allergy Clin Immunol 125(2, suppl 2):S41-S52.
37. Brooks CL, et al. (2010) The role of CDR H3 in antibody recognition of a synthetic analog of a lipopolysaccharide antigen. Glycobiology 20(2):138-147.
38. Müller-Loennies S, Brade L, Brade H (2007) Neutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharide. Int J Med Microbiol 297(5):321-340.
39. Rietschel ET, et al. (1996) Bacterial endotoxin: Chemical constitution, biological recognition, host response, and immunological detoxification. Curr Top Microbiol Immunol 216:39-81.
40. Weinand RG (1990) Somatic mutation, affinity maturation and the antibody repertoire: A computer model. J Theor Biol 143(3):343-382.
41. Golding GB, Gearhart PJ, Glickman BW (1987) Patterns of somatic mutations in immunoglobulin variable genes. Genetics 115(1):169-176.
42. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC (1997) Structural insights into the evolution of an antibody combining site. Science 276(5319):1665-1669.
43. de StGroth SF, Scheidegger D (1980) Production of monoclonal antibodies: Strategy and tactics. J Immunol Methods 35(1-2):1-21.
44. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(pt 4): 658-674.
45. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
46. Adams PD, et al. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66(pt 2):213- 221.
47. Ruiz M, et al. (2000) IMGT, the international ImMunoGeneTics database. Nucleic Acids Res 28(1):219-221.